SCHEMBL6500654

SCHEMBL6500654

CCc1ccc(C2=C(C(=O)Nc3ccc(N(C=O)CCc4ccccn4)cc3)CCCC2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 8/20 0.44
NPC1 O15118 6/20 0.43
KMT2A Q03164 2/20 0.43
LMNA P02545 2/20 0.43
MEN1 O00255 1/20 0.43
KDM4E B2RXH2 4/20 0.40
POLB P06746 2/20 0.40
TDP1 Q9NUW8 2/20 0.40
TSHR P16473 1/20 0.40
ALDH1A1 P00352 4/20 0.39
SMN1; SMN2 Q16637 6/20 0.39
MAPT P10636 2/20 0.39
HTT P42858 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
CHRM5 P08912 1/20 0.38
CHRM1 P11229 1/20 0.38
RCE1 Q9Y256 1/20 0.37
HSD17B10 Q99714 1/20 0.36
ESR1 P03372 1/20 0.36
NR4A1 P22736 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6489397 0.93 L3MBTL1 (0.41) RAB9ANPC1KMT2AMEN1KDM4E
SCHEMBL6501910 0.92 L3MBTL1 (0.40) RAB9ANPC1KMT2AMEN1KDM4E
SCHEMBL6501907 0.92 L3MBTL1 (0.40) RAB9ANPC1KMT2AMEN1KDM4E
SCHEMBL6489838 0.92 L3MBTL1 (0.40) RAB9ANPC1KMT2AMEN1KDM4E
SCHEMBL6500051 0.91 L3MBTL1 (0.41) RAB9ANPC1KMT2AMEN1KDM4E
SCHEMBL6503585 0.88 TRPV1 (0.43) KMT2ALMNAPKM
SCHEMBL6497545 0.88 TRPV1 (0.43) KMT2ALMNAPKM
SCHEMBL6497530 0.88 TRPV1 (0.43) KMT2ALMNAPKM
SCHEMBL6498966 0.87 TRPV1 (0.43) KMT2ALMNAMAPTPKM
SCHEMBL6491912 0.84 RAB9A (0.48) RAB9ANPC1KMT2ALMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors DAISO CO., LTD. (JP) 2005-02-17 US disclosed
EP-1472226-A1 HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-11-03 EP disclosed
WO-2003045921-A1 HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors APOB, APOL1, CTRB2 RAB9A 4382/4885NPC1 100/4885KMT2A 573/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.